Featured
The Reimbursement Moat: How Medicare’s Outcomes Mandate and CRISPR Approvals Are Rewiring Biotech Valuations
The FDA’s approval of an in vivo CRISPR therapy and Medicare’s new outcomes-based rebate framework are fundamentally altering biotech valuations, ...
Read Full Story →